These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 8701815)

  • 1. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 5. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 6. [Significance of neoadjuvant therapy for prostate cancer].
    Okada K; Hachiya T
    Nihon Hinyokika Gakkai Zasshi; 1997 Sep; 88(9):769-77. PubMed ID: 9364842
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy.
    Cellini N; Luzi S; Morganti AG; Valentini V; Mantini G; Racioppi M; Smaniotto D; Leone M; Mattiucci GC; Digesù C; Giustacchini M; Destito A; Alcini E
    Urol Int; 2004; 72(1):21-7. PubMed ID: 14730161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
    Schulman CC; Wildschutz TP
    Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
    [No Abstract]   [Full Text] [Related]  

  • 10. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
    Mazeron JJ; Simon JM; Toubiana T; Lang P
    Bull Cancer; 2005 Dec; 92(12):1078-84. PubMed ID: 16396754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant medical therapy for prostate cancer.
    Sumey C; Flaig TW
    Expert Opin Pharmacother; 2011 Jan; 12(1):73-84. PubMed ID: 21118060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
    Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
    [No Abstract]   [Full Text] [Related]  

  • 15. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L; Schellhammer P; Carroll K
    BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
    Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and prostate cancer.
    Dacker R
    Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of prostate cancer with goserelin and radiotherapy.
    Vicini FA; Kini VR; Martinez AA
    N Engl J Med; 1997 Dec; 337(23):1693-4. PubMed ID: 9411236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.